Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035880 · ClinicalTrials.gov registry record · Phase 2
Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease
A Phase 2 study, sponsored by Abgenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT00035880 is a Phase 2 study that has completed, run by Abgenix. The registered enrollment target is 95 participants.
The verdict
NCT00035880, a Phase 2 study, has completed, sponsored by Abgenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.
Interventions
- DRUG ABX-CBL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 1999-10 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035880
The ClinicalTrials.gov registry entry for NCT00035880 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abgenix, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABX-CBL is the first listed.
NCT00035880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035880 about?
NCT00035880 is a clinical study titled "Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease". Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.
What is the current status of trial NCT00035880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 1999-10. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00035880?
The interventions under investigation include: ABX-CBL (DRUG).
Who is sponsoring clinical trial NCT00035880?
This trial is sponsored by Abgenix, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.